Skip to main content

Advertisement

Table 1 Percent changes (Δ-values are differences between means) in c-MYB and ESPL1/Separase transcript and protein levels under IM treatment when compared to corresponding untreated cells

From: c-MYB is a transcriptional regulator of ESPL1/Separase in BCR-ABL-positive chronic myeloid leukemia

Cell line, dose and period of treatment c-MYB transcript levelsa c-MYB protein levelsb ESPL1 transcript levelsa Separase protein levelsb
LAMA-84, 2.5 μM IM, 24 h −88.8 ± 4.4, p < 0.0001 −25.7 ± 9.6, p = 0.0233 −90.3 ± 3.3, p < 0.0001 −75.8 ± 16.8, p = 0.0064
K562, 1 μM IM, 24 h −82.4 ± 4.4, p < 0.0001 −37.1 ± 9.6, p = 0.0082 −25.0 ± 9.7, p = 0.0328 −53.1 ± 4.4, p = 0.0015
U937, 5 μM IM, 48 h −9.1 ± 2.9, p = 0.0363 +9.8 ± 10.2, p = 0.3942 −8.1 ± 9.5, p = 0.4198 −10.5 ± 11.2, p = 0.3775
  1. a Δ-values [%] were calculated from at least triplicate qRT-PCR experiments and were normalized to the housekeeping gene Gus
  2. b Δ-values [%] are derived from at least triplicate Western blot immunostaining experiments. All protein values were normalized to Actin as loading control
  3. Abbreviations: d days, h hours, IM imatinib; + increase, − decrease